In Vivo Dosimetry Analysis of Thyroid Gland Dose in Breast Cancer Patients with Supraclavicular Lymph Node Irradiation

2010 ◽  
Vol 78 (3) ◽  
pp. S716-S717
Author(s):  
L. Peres ◽  
M.L. Reisner ◽  
C.L.P. Maurício ◽  
H. Salmon ◽  
P.C.V. Canary
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Thyroid Gland ◽  
Cancer Patients ◽  
In Vivo Dosimetry ◽  
Breast Cancer Patients ◽  
Supraclavicular Lymph Node ◽  
Lymph Node Irradiation

scholarly journals Risk of Radiation Induced Carotid Artery Stenosis in Supraclavicular Lymph Node Irradiation in Breast Cancer Patients

2014 ◽  
Vol 05 (03) ◽  
pp. 238-245 ◽  
Author(s):  
Reham Abdulmoniem ◽  
Yasser Bayoumi ◽  
Mushabbab Al Asiri ◽  
Reem Zatar ◽  
Abdullah Al Amro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Carotid Artery ◽  
Cancer Patients ◽  
Carotid Artery Stenosis ◽  
Artery Stenosis ◽  
Breast Cancer Patients ◽  
Supraclavicular Lymph Node ◽  
Radiation Induced ◽  
Lymph Node Irradiation

scholarly journals Surgery of the Primary Tumor Offers Survival Benefits of Breast Cancer with Synchronous Ipsilateral Supraclavicular Lymph Node Metastasis

2019 ◽  
Vol 44 (4) ◽  
pp. 1163-1172
Author(s):  
Qi-tong Chen ◽  
Li-yun Zeng ◽  
Deng-jie Ouyang ◽  
Piao Zhao ◽  
Qiong-yan Zou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Resection ◽  
Seer Database ◽  
Breast Cancer Patients ◽  
Supraclavicular Lymph Node ◽  
Node Metastasis ◽  
Supraclavicular Lymph Node Metastasis

Abstract Background Controversy exists around the locoregional management of the primary tumor for breast cancer associated with synchronous ipsilateral supraclavicular lymph node metastasis (sISLM) due to the rarity of the disease and limited available data. This study aimed to compare outcomes of patients in the Surveillance, Epidemiology, and End Results (SEER) database with sISLM who underwent surgical resection and radiation of the primary tumor with those who did not. Methods This population-based retrospective study included breast cancer patients with sISLM without distant metastases from 2004 to 2016 in the SEER database. In this study, patients had been stratified by operative management, and propensity score matching (PSM) had been successfully applied. Results A total of 1172 breast cancer patients with sISLM were included in the study: 863 (73.6%) of patients underwent the primary tumor resection, and 309 (26.4%) patients did not undergo surgery. The median survival time in the surgery group was longer compared to the nonsurgery group in the overall cohort and the PSM cohort. We concluded that the primary tumor resection was associated with improved survival. Subgroup analysis further demonstrated that local surgery was not inferior to radical surgery. Conclusion For selected breast cancer patients with sISLM, surgery is a promising local intervention which may improve the survival.

scholarly journals Prospective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapy

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Sebastian Höfel ◽  
Matteo Gandalini ◽  
Michael K. Fix ◽  
Malte Drescher ◽  
Felix Zwicker
Keyword(s):  
Breast Cancer ◽  
Total Dose ◽  
Cancer Patients ◽  
Helical Tomotherapy ◽  
Planning System ◽  
In Vivo Dosimetry ◽  
Breast Cancer Patients ◽  
Displacement Vectors ◽  
The Mean

Abstract Background In-vivo dosimetry (IVD) is a patient specific measure of quality control and safety during radiotherapy. With regard to current reporting thresholds for significant occurrences in radiotherapy defined by German regulatory authorities, the present study examines the clinical feasibility of superficial electron paramagnetic resonance (EPR) IVD of cumulative total doses applied to breast cancer patients treated with helical intensity-modulated radiotherapy (tomotherapy). Methods In total, 10 female patients with left- or right-sided breast cancer were enrolled in this prospective IVD study. Each patient received a hypofractionated whole breast irradiation. A total median dose of 42.4 Gy in 16 fractions (5 fractions per week) was prescribed to the planning target volume. The treatments were completely delivered using helical tomotherapy and daily image guidance via megavoltage CT (MVCT). For each patient, three EPR dosimeters were prepared and placed at distinct locations on the patient’s skin during the delivery of all fractions. Two dosimeters were placed next to the ipsilateral and contralateral mammilla and one dosimeter was placed ventrally to the thyroid (out-of-primary-beam). The total doses delivered to the dosimeters were readout after all fractions had been administered. The measured total dose values were compared to the planned dose values derived from the treatment planning system (TPS). Daily positional variations (displacement vectors) of the ipsilateral mammilla and of the respective dosimeter were analyzed with respect to the planned positions using the daily registered MVCT image. Results Averaged over all patients, the mean absolute dose differences between measured and planned total dose values (± standard deviation (SD)) were: 0.49 ± 0.85 Gy for the ipsilateral dosimeter, 0.17 ± 0.49 Gy for the contralateral dosimeter and -0.12 ± 0.30 Gy for the thyroid dosimeter. The mean lengths of the ipsilateral displacement vectors (± SD) averaged over all patients and fractions were: 10 ± 7 mm for the dosimeter and 8 ± 4 mm for the mammilla. Conclusion Superficial EPR IVD is suitable as additional safeguard for dose delivery during helical tomotherapy of breast cancer. Despite positional uncertainties in clinical routine, the observed dose deviations at the ipsilateral breast were on average small compared to national reporting thresholds for total dose deviations (i.e. 10%/4 Gy). EPR IVD may allow for the detection of critical dose errors during whole breast irradiations.

Sign in / Sign up

Export Citation Format

Share Document